Department of Thoracic Surgery, University Hospitals Leuven, Leuven, Belgium; Department of Chronic Diseases and Metabolism, Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE), KU Leuven, Leuven, Belgium.
Department of Thoracic Surgery, University Hospitals Leuven, Leuven, Belgium; Department of Chronic Diseases and Metabolism, Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE), KU Leuven, Leuven, Belgium.
J Heart Lung Transplant. 2022 Jun;41(6):745-754. doi: 10.1016/j.healun.2022.01.1375. Epub 2022 Feb 3.
Organ transplantation is hampered by shortage of suitable organs. In countries with a legal framework, organ donation following euthanasia is an option labeled "donation after cardio-circulatory death category V" (DCD-V). We describe our experience with lung transplantation (LTx) after euthanasia and evaluate post-transplant outcome using a matched comparison to DCD-III (withdrawal from life-sustaining therapy) and donation after brain death (DBD).
All bilateral LTx between 2007 and 2020 were retrospectively analyzed. Matching was performed for recipient age and gender, indication for LTx, mean pulmonary artery pressure, extracorporeal life support, and donor age, which resulted in 1:2 DCD-III and 1:3 DBD matching. Primary graft dysfunction (PGD), chronic lung allograft dysfunction (CLAD), and patient survival were analyzed.
A total of 769 LTx were performed of which 22 from DCD-V donors (2.9%). Thirteen women and 9 men expressed their wish to become organ donor after euthanasia. Euthanasia request was granted for irremediable neuromuscular (N = 9) or psychiatric (N = 8) disorder or unbearable and unrecoverable pain (N = 5). PGD (grade 3, within 72 hours post-transplant) was 23.8% in the DCD-V cohort, which is comparable to DCD-III (27.9%; p = 1.00) and DBD (32.3%; p = .59). CLAD-free 3- and 5-year survival were 86.4% and 62.8%, respectively, and comparable to DCD-III (74.4% and 60.0%; p = .62) and DBD (72.6% and 55.5%; p = .32). Five-year patient survival was 90.9%, not significantly different from both DCD-III (86.0%; p = 1.00) and DBD (78.1%; p = .36).
We observed that LTx with DCD-V allografts is feasible and safe, yielding no evidence for differences in short- and long-term outcome compared to matched cohorts of DCD-III and DBD.
器官移植受到合适器官短缺的阻碍。在有法律框架的国家,安乐死后器官捐献是一种被标记为“心死亡分类 V 捐献”(DCD-V)的选择。我们描述了我们在安乐死后进行肺移植(LTx)的经验,并使用与 DCD-III(停止生命支持治疗)和脑死亡后捐献(DBD)的匹配比较来评估移植后的结果。
回顾性分析了 2007 年至 2020 年间所有双侧 LTx。根据受体年龄和性别、LTx 指征、肺动脉平均压、体外生命支持以及供体年龄进行匹配,结果为 1:2 的 DCD-III 和 1:3 的 DBD 匹配。分析了原发性移植物功能障碍(PGD)、慢性肺移植物功能障碍(CLAD)和患者存活率。
共进行了 769 例 LTx,其中 22 例来自 DCD-V 供体(2.9%)。13 名女性和 9 名男性表示希望在安乐死后成为器官捐献者。安乐死请求被批准用于无法治愈的神经肌肉(N=9)或精神疾病(N=8)或无法忍受和无法恢复的疼痛(N=5)。DCD-V 组的 PGD(移植后 72 小时内 3 级)为 23.8%,与 DCD-III(27.9%;p=1.00)和 DBD(32.3%;p=0.59)相当。CLAD 无 3 年和 5 年生存率分别为 86.4%和 62.8%,与 DCD-III(74.4%和 60.0%;p=0.62)和 DBD(72.6%和 55.5%;p=0.32)相当。5 年患者生存率为 90.9%,与 DCD-III(86.0%;p=1.00)和 DBD(78.1%;p=0.36)无显著差异。
我们观察到 DCD-V 同种异体移植物的 LTx 是可行和安全的,与 DCD-III 和 DBD 的匹配队列相比,没有证据表明短期和长期结果存在差异。